The carbohydrate response element-binding protein (ChREBP) is a glucose-regulated basic helix--loop--helix (bHLH) transcription factor that acts as a key regulator of enzymes involved in fatty acid synthesis. In response to increased glucose levels, ChREBP undergoes dephosphorylation steps that allow translocation from the cytoplasm to the nucleus where, in association with its binding partner MLX (Max-like interacting protein), it binds to the carbohydrate response element of lipogenic genes ([@bib33]; [@bib15]; [@bib28]).

Evidence indicates that ChREBP may have a role in cancer pathology and the mechanisms associated with tumourigenesis. In particular, a link between ChREBP and the suppression of p53-induced cell cycle arrest has been revealed in transformed cells that takes place via the reprogramming of metabolism to favour aerobic glycolysis ([@bib32]), an established hallmark of tumour metabolism ([@bib2]; [@bib3]; [@bib29]; [@bib5]). Furthermore, genomic analysis of ChREBP target gene expression in the hepatoma HEPG2 cell line shows a dual association with pathways associated with the tumour metabolic phenotype as well as with malignant progression, such as differentiation and motility ([@bib22]).

The metabolic shift from one that is dominated by oxidative phosphorylation to that of increased glycolytic flux is manifested by increased glucose flux and often overexpression of the hypoxia-inducible factor-1 (HIF-1)- regulated facilitative glucose transporter Glut-1, alongside the associated upregulation of glycolytic enzymes ([@bib2]). Metabolomic analysis also indicates that Glut-1 facilitates a HIF-1-independent rise in the production of metabolites associated with phospholipid metabolism and cell turnover, for example phosphatidyl choline ([@bib16]). The sequence homology between the ChRE and the hypoxia response element (HRE) in the promoter of HIF-1 target genes, meanwhile, suggests that there may be a cross-talk or at least coordination of ChREBP and HIF-1-regulated pathways within the spatially and temporally heterogeneous tumour microenvironment ([@bib13]).

So far, much of the work surrounding ChREBP has focussed on its function as a liver transcription factor, its activation by glucose metabolites and role in the regulation of lipogenesis. This may have implications for breast cancer pathology. First, breast cancer is mechanistically and epidemiologically linked with obesity ([@bib8]; [@bib24]), suggesting a causal link with deregulated lipid metabolism. Second, glycolytic and lipogenic pathways may behave as integrated features of tumour metabolism brought about via loss of p53, activation of Akt and changes in the expression and functionality of lactate dehydrogenase ([@bib37]).

The aim of this study was to investigate ChREBP expression in breast cancer and how this may be associated with Glut-1 expression and malignant progression in the context of published genomic analysis of the hypoxic tumour microenvironment.

Materials and methods
=====================

Materials
---------

Unless stated otherwise, all reagents were obtained from Sigma (Dorset, UK). Histology glass wear and mounting medium were purchased from Thermo Scientific (Loughborough, UK). Cell lines were obtained from ATCC (Teddington, UK) (LGC standards) and had been authenticated according to in-house procedures.

Tissue microarrays
------------------

Tissue microarrays used in this study included the Accumax (Cepheid UK Ltd, Stretton, UK) (A712) breast cancer test array that carried samples from 12 cases of breast cancer paired with normal adjacent tissue. In addition, two separate breast cancer progression arrays were also used: the Cybrdi Inc (Rockville, MD, USA, CC08-00-005) array that contains 71 individual cases of adenosis, fibroadenoma, tumour to metastasis, and the Biomax (Insight Biotechnology, Wembley, Middlesex, UK, BR2082) array that contains a total of 206 cases made up of 32 samples of metastatic carcinoma, 68 invasive ductal carcinoma, 22 each of lobular carcinoma and intraductal carcinoma, 4 each of squamous cell carcinoma and lobular carcinoma *in situ*, 8 fibroadenoma, 16 each of hyperplasia and inflammation, 10 adjacent normal tissue and 6 normal tissue. Information on clinical and pathological characteristics as well as ethical considerations is available on the website of, or upon request from, the commercial tissue microarray suppliers. These studies were carried out after approval by the institutional ethical review committee (University of Huddersfield, Huddersfield, USA).

Immunohistochemistry
--------------------

Immunohistochemistry was carried out as per established protocols, with primary antibody steps consisting of a 1 : 100 dilution of rabbit anti-Glut-1 (Alpha Diagnostic International, San Antonio, TX, USA) or a 1 : 400 dilution of rabbit anti-ChREBP (Abcam, Cambridge, UK). For ChREBP immunostaining, antigen retrieval was carried out by boiling slides for 20 min in 10 m[M]{.smallcaps} citrate buffer. A commercially available kit (Menorini Diagnostics, Reading, UK) that consists of a universal rabbit/mouse secondary probe and a horseradish peroxidase or alkaline phosphatase enzyme polymer conjugate plus chromogen was used for visualisation.

Antibody specificity
--------------------

The specificity of the rabbit anti-ChREBP used for the immunohistochemical analysis of the tissue microarrays was determined by western analysis of a ChREBP knockdown cell line generated from MCF-7 cells. This revealed a sharp decrease in expression in early passages with a return to wild-type levels within five passages. This apparent reversal of knockdown was confirmed by qRT--PCR analysis (shown in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Although this confirms the specificity of the antibody, further work will be needed to determine whether the changes in ChREBP expression relates to a technical problem with the generation of the cell lines or is a biological adaptation to reduced ChREBP expression.

The ChREBP knockdown MCF-7-derived cell line and subsequent western and qRT--PCR analyses were carried out.

Generation of ChREBP knockdown MCF7-derived cell line
-----------------------------------------------------

A ChREBP knockdown cell line and scrambled vector control were generated using reagents obtained from Santa Cruz Biotechnology (Dallas, TX, USA). MCF7 cells were transfected with CHREBP shRNA (h) lentiviral particles (sc-38617-V) using Polybrene (Sigma) as per the manufacturer\'s protocol. These were used alongside control shRNA lentiviral particles (sc-108080). Stable clones were selected after placing in DMEM containing 2 *μ*g ml^−1^ puromycin (Santa Cruz Biotechnology).

Western blot
------------

Cell lysates were prepared according to standard protocols and the equivalent to 20 *μ*g protein samples was run on NuPAGETM Novex electrophoresis pre-cast gels (Invitrogen, Life Technologies, Paisley, UK) followed by transfer onto a PVDF transfer membrane of pore size 0.45 *μ*m (Immobilon-P Polyvinylidine difluoride, Millipore, Watford, UK). Membranes were blocked with 1% (w/v) casein before overnight incubation at 4 °C with rabbit anti-ChREBP diluted with SignalBoostImmunoreaction Enhancer primary antibody solution (Merck Chemicals, Watford, UK) according to the manufacturer\'s instructions. The membranes were visualised using an Odyssey Infra-red Imaging system (Li-Cor, Lincoln, NE, USA), using *β*-actin antibody as a loading control.

qRT--PCR analysis
-----------------

Total RNA was extracted using Tri Reagent (Sigma) as per the manufacturer\'s instructions. The quantities and qualities of RNA from each sample were assessed by gel agarose electrophoresis as well as spectrophotometry using a NanoDrop 2000 (Thermo Scientific). Then, 1 *μ*g of RNA was incubated in a total volume of 10 *μ*l containing 1 *μ*l of 10 × DNase I reaction buffer and 1 *μ*l (1 U *μ*l^−1^) of DNase I at 37 °C for 30 min with subsequent inactivation at 65 °C for 15 min with 1 *μ*l 25 m[M]{.smallcaps} EDTA. The cDNA was synthesised in a 20 *μ*l volume with oligo(dT)20 (Invitrogen) and SuperScript III First-Strand Synthesis SuperMix (Invitrogen). The reactions were incubated at 50 °C for 1 h and then inactivated by heating at 70 °C for 15 min. The RNase H (Invitrogen) was added, 1 *μ*l (1 U *μ*l^−1^) to each preparation, and incubated for 20 min at 37 °C.

In each qRT--PCR reaction, 5 ng of template cDNA was used in a total volume of 15 *μ*l containing water, 7.5 *μ*l of iTaq Universal SYBR Green 2x Supermix (Bio-Rad, Herts, UK) and the appropriate primer set (Eurofins MWG Operon, Ebersberg, Germany; see [Supplementary Information](#sup1){ref-type="supplementary-material"} for primer sequences) at a final concentration of 100 n[M]{.smallcaps}. The qRT--PCR assays were performed on a Bio-Rad CFX96 Touch Real-Time PCR Detection System using the following PCR conditions: 15 min at 95 °C followed by 50 cycles of 15 s denaturing at 95 °C and 60 s annealing at 60 °C. A reverse transcriptase negative control was used to assess whether any residual genomic DNA remained and a no-template control was included to examine primer-dimer formation. The qRT--PCR experiments were excluded for analysis if the reaction efficiency was outside the range of 0.9--1.1 or if the *r*^2^ value of the linear regression was \<0.95. For the qPCR analysis, the relative normalised expression (ΔΔCq) method was determined using *RPL30* as a reference gene. The normalised data from the various cell lines were analysed using the Bio-Rad CFX manager software 3.0 and fold change determined.

Semiquantitative and statistical analysis
-----------------------------------------

Semiquantitative scoring was carried out as in previous studies ([@bib16]) where, briefly, tissue microarray sample 'spots\' were viewed at low magnification ( × 200) and an overall score assigned according to intensity and area of immunostaining staining. [Supplementary Figure S2](#sup1){ref-type="supplementary-material"} shows representative examples of sample scoring as follows: 0, no; 1, light; 2, moderate; and 3, heavy staining. To determine interobserver variation, the first 30 samples of the Biomax (BR2082) array were scored by two observers (REA and WA-T) (ChREBP *r*=0.854, *P*\<0001, *n*=30); the intraobserver variation was measured using scores made by the primary observer (WA-T) on the Biomax (BR2082) array 3 weeks apart (Spearman\'s rank correlation: (Glut-1) *r*=0.843, *P*\<0.001, *n*=32 (ChREBP) *r*=0.952, *P*\<0.001, *n*=32).

Bioinformatic analysis
----------------------

The derivation of a common hypoxia signature or 'hypoxia metagene\', together with a breast cancer-specific hypoxia signature, has been described previously and may be used to provide both prognostic information in the clinic. It also provides data that allow us to integrate gene function and derive further hypotheses with which to investigate how pathways directed by hypoxia are associated with deregulated metabolism within the tumour microenvironment ([@bib17]; [@bib6]). These have been used to compile up- and down-regulated hypoxia gene signatures using in *vitro* and *in vivo* data sets that charted changes in the expression of these genes in hypoxic conditions alongside the involvement of hypoxia-inducible factor HIF-1. A large number, although not all, of these hypoxia-regulated genes are HIF-1 target genes ([@bib7]). The Oxf-IJB breast cancer series and other published data sets were used for expression analysis and have been described previously ([@bib6]). For comparison, this included the Curtis breast cancer series of 2136 breast tumours ([@bib12]) via Oncomine (Compendia Biosciences, Ann Arbor, MI, USA).

Results
=======

ChREBP immunohistochemistry in tissue microarrays
-------------------------------------------------

Immunohistochemical profiling of ChREBP protein expression in tissue microarrays was carried out to determine whether there is differential expression in breast tumours of mixed pathologies relative to adjacent nonmalignant breast tissues. The overexpression of Glut-1 observed in breast and other cancers ([@bib4]; [@bib1]) may provide glucose metabolites with which to activate ChREBP signalling, and therefore we also carried out Glut-1 immunohistochemical analysis in the same tissue microarrays to observe any colocalisation and correlation between Glut-1 and ChREBP. In general, ChREBP immunostaining was found in the cytoplasm and the nucleus. The subcellular location in the nucleus is because of dephosphorylated (active) ChREBP, wherein it is capable of forming a DNA-binding complex ([@bib25]).

Initially, we used a low-density tissue microarray (Accumax A712) to look for any differences in the pattern of ChREBP expression between breast tumours and adjacent normal tissue that would allow preliminary assessment of ChREBP as a biomarker of malignancy in this tissue type ([Figure 1](#fig1){ref-type="fig"}). The data from this array showed 5 out of 12 cases clearly expressing ChREBP protein in malignant but not adjacent normal tissue, but 7 out of 12 cases stained positive for ChREBP in both, although the ChREBP staining was at a lower level in normal tissue when present. There was a similarity in localisation between ChREBP and Glut-1 expression in serial sections found in areas of both normal and malignant breast tissue.

To reveal a possible link between ChREBP protein and the histopathology of malignant progression, we used two commercially available breast progression arrays that provided us with samples from two independent series of breast cancer cases. [Figure 2](#fig2){ref-type="fig"} shows representative ChREBP immunostaining in the Cybrdi (CC08-00-005) breast progression array, where staining scores showed a clear trend for increasing with the malignant progression as defined by histopathological diagnosis. Although nonmalignant and inflammatory or hyperplastic tissue tended not to express ChREBP and, if so, at low levels, malignant, infiltrating and metastatic breast tumour tissue was virtually always associated with moderate or heavy ChREBP staining. A similar trend was seen with the Biomax (BR2082) array that also carried a progression of breast histopathologies but with a larger series of cases. In this series, moderate or heavy ChREBP staining was only apparent in invasive tumours, whereas normal tissue, nonmalignant hyperplasia and carcinoma *in situ*, in all but 2 cases, showed no ChREBP staining at all. Furthermore, Glut-1 and ChREBP scores were significantly correlated (Spearman\'s rank correlation: *r*=461, *P*\<0.001, *n*=207). Categorisation into normal, benign hyperplastic/inflammatory, *in situ* (localised), invasive and metastatic histopathology produced a statistically significant increase in mean immunohistochemical score in both the Cybrdi and Accumax progression arrays, although a significant reverse trend was observed when considering mean ChREBP mRNA expression and malignant progression by similar histopathological designation in the Curtis series of breast cancer cases (2136 patients) via Oncomine ([Figure 3A](#fig3){ref-type="fig"}).

Clinical correlates of ChREBP protein and mRNA expression with survival
-----------------------------------------------------------------------

Kaplan--Meier analysis did not show a significant relationship between grouped ChREBP protein scores in the Oxf-IJB breast cancer series with either overall (*P*=0.1) or relapse-free (*P*=0.6) survival in this cohort of patients. However, an analysis of survival data from the Curtis series showed ChREBP mRNA expression to not only be significantly correlated with increased survival (log rank *P*\<0.001; MLXIPL ILMN_1722073; [Figure 3B](#fig3){ref-type="fig"}) but also show a trend for decreased expression with grade and an overexpression in normal adjacent tissue and benign cases relative to malignant tissue (illustrated by heat maps generated via Oncomine, see [Supplementary Slides](#sup1){ref-type="supplementary-material"}). A similar trend for increased survival was observed with the ChREBP reporter MLXIPL ILMN_2399919 but this was not significant (*P*=0.091). When stratified by molecular subtype, there remained a significant increased likelihood of survival with high ChREBP (MLXIPL ILMN_1722073) mRNA expression in oestrogen receptor (ER)-positive cases (log rank *P*=0.014), ErbB2-negative (log rank *P*=0.004) and nontriple-negative (log rank *P*\<0.001) breast cancer. A differential analysis of ChREBP expression by ER status via Oncomine also revealed a significant overexpression (MLXIPL ILMN_1722073 1.082-fold change, *t-*test: 6.219, *P*=4.02E--10; ILMN_2399919, *t-*test: 4.629, *P*=2.17E--6) in a subgroup of ER-positive invasive ductal breast carcinoma within the Curtis breast series.

Clinical correlates of ChREBP protein and mRNA expression with hypoxia
----------------------------------------------------------------------

Analysis of the relationship between ChREBP expression and the breast hypoxia gene signature revealed a significant correlation between ChREBP protein and mean 'downregulated\' hypoxia scores (*r*=0.3, *P*=0.014, *n*=67), which was weaker but consistent at mRNA level (*r*=0.134, *P*=0.2, *n*=67) There was also a significant anticorrelation between ChREBP protein and median 'upregulated\' hypoxia scores (*r*=−0.246, *P*=0.04, *n*=67). There was, however, no relationship to scores derived from either the up- or downregulated lactate signature described by [@bib10]).

The ChREBP mRNA levels mined from an extended series of 232 cases analysed using an Illumina (San Diego, CA, USA) platform correlated significantly with both mean and median 'downregulated\' hypoxia scores, and as expected remained anticorrelated with mean and median 'upregulated\' hypoxia scores ([Figure 4](#fig4){ref-type="fig"}). In the same data set, ChREBP mRNA was also anticorrelated with individual hypoxia-inducible genes such as *CA9* (*r*=−0.215, *P*=0.001) and *LDHA* (*r*=−0.213, *P*=0.001) and, in contrast with the significant positive correlation shown by protein forms in the BRC 711 tissue microarray, ChREBP and Glut-1 mRNA in the Illumina data set were also significantly anticorrelated (*r*=−0.212, *P*=0.001). A similar anticorrelation between ChREBP mRNA expression and these hypoxia-regulated genes was observed qualitatively in the Curtis breast series, as shown in heat maps generated via Oncomine ([Supplementary Slides](#sup1){ref-type="supplementary-material"}) and in an extended correlative analysis ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Correlates of ChREBP mRNA with ChREBP target genes
--------------------------------------------------

[@bib22]) carried out a comprehensive ChIP sequence analysis of ChREBP target expression in human hepatocellular carcinoma HEPG2 cells and we used these to analyse the human breast cancer data sets. [Table 1](#tbl1){ref-type="table"} shows the correlative relationships existing within the Oxf-IJB (Illumina) series of 232 patients between the level of ChREBP mRNA and that of its target genes previously identified by [@bib22]). This was with the aim of highlighting any functional similarities or differences in the nature of ChREBP signalling in the hepatocellular carcinoma cell line used by [@bib22]) and breast cancer. ChREBP mRNA expression, mined from the Illumina data set, correlated positively with the expression of all genes identified in the study of [@bib22]) as upregulated by ChREBP apart from *pyruvate dehydrogenase kinase 2* (*PDK2*). For genes identified as downregulated by ChREBP, although ChREBP mRNA mined from the Illumina data set mostly showed concordant negative regulation of these target genes, there was a positive correlation with the expression of phosphoenolpyruvate carboxykinase (PEPCK). The distributions of these data in relation to median expression of all mRNAs in the Illumina data set are presented as box-and-whisker plots in [Figure 5](#fig5){ref-type="fig"}. A strongly significant positive correlation between ChREBP and PEPCK was also found in the analysis of the Curtis breast series ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Discussion
==========

So far, there has been limited investigation of a possible role for ChREBP in tumour pathology or as a biomarker of malignancy. One previous study has shown no relationship between single-nucleotide polymorphism of either ChREBP or FASN and breast cancer risk ([@bib9]). The differential staining between normal adjacent and malignant tissue, as well as the clear increase in *de novo* expression of ChREBP protein with malignant progression, therefore suggests that local rather than genomic changes in ChREBP may have a role in driving tumourigenesis. It is puzzling that the majority of ChREBP expression appeared to be the cytoplasmic, phosphorylated and therefore inactive transcription factor. However, ChREBP exists in multiple isoforms that might vary in their tissue and tumour specificity as well as their up- and downstream regulatory effects. One recent study identified a regulatory path existing between the canonical ChREBP*α* isoform and ChREBP*β*, where ChREBP*β* is induced by ChREBP*α* via an alternative promoter in adipose tissue and predicts insulin sensitivity. This suggests that there might be not only an element of cross-talk between malignant breast and surrounding normal adipose tissue, but also that *de novo* synthesis of ChREBP may be partially self-regulated and critical to the changes in insulin-signalling that are a feature of breast tumour pathology and linked with cell proliferation and survival. The ChREBP association with insulin signalling and the correlation we have observed with Glut-1 may also determine how it interacts with important breast tumourigenic pathways such as the ER, epidermal growth factor receptor (EGFR), the insulin-like growth factor (IGF) systems and the mammalian target of rapamycin (mTOR) pathways ([@bib26]; [@bib34]; [@bib36]).

Relationship between ChREBP protein and mRNA expression
-------------------------------------------------------

The major function of ChREBP is the regulation of lipogenesis. However, HIF-1 and ChREBP share a function; to carry out their respective control of catabolic and anabolic pathways, they upregulate the expression of glycolytic genes. This increased rate of glycolysis is limited by a negative feedback mechanism mediated by the induction of TXNIP (thioredoxin interacting protein), a feedback mechanism common to both transcription factors ([@bib38]). Much of the understanding of the mechanistic effects of ChREBP has come about through studies involving cultured hepatocytes, where it has been observed that polyunsaturated but not saturated or monounsaturated fats suppress *de novo* synthesis of ChREBP, and that overexpression of ChREBP abolishes this effect ([@bib14]). In addition, ChREBP is deactivated via activation of adenosine monophosphate-activated kinase (AMPK) that takes place in conditions where the AMP/ATP ratio is high, a consequence of increased diversion of the end products of glycolysis into fatty acid synthesis rather than oxidative phosphorylation ([@bib21]). Therefore, the existence of a negative feedback mechanism, although a complex one, where the induction of fatty acid synthesis by active nuclear ChREBP leads to eventual suppression of ChREBP mRNA synthesis, but where initial activation of existing ChREBP necessitates an increased rate of glucose uptake and metabolism, may exist. In breast tumours, this mechanism may be dependent upon the bioenergetic flux brought about by interacting populations of normoxic and hypoxic tumour and adipose tissue. The apparent inversion of the effects of ChREBP protein and mRNA on breast cancer progression, survival and the expression of hypoxia-regulated genes may be a reflection of such a mechanism.

Relationship between ChREBP and a normoxic malignant phenotype
--------------------------------------------------------------

Using a metabolomic approach, we have shown in a previous study that hypoxic conditions, particularly in the absence of an intact HIF-1 response, are countered by a rise in the AMP/ATP ratio and the subsequent activation of the glycolytic enzyme phosphofructokinase (PFK-1) and AMPK ([@bib20]). The rise in the AMP/ATP ratio is also a key regulatory feature of AMPK-activated phosphorylation and inactivation of ChREBP, a feedback mechanism that downregulates ChREBP transcription in response to ChREBP-induced fatty acid synthesis ([@bib23]; [@bib18]). The current findings highlight a correlation between ChREBP expression and the downregulated breast hypoxia signature, suggesting that ChREBP is expressed in normoxic conditions and a possible link with the suppression or downregulation of hypoxia and HIF-1-regulated genes. One explanation may be that, in hypoxic conditions, the activation of AMPK leads to downregulation of ChREBP and consequently fatty acid synthesis, favouring instead the B-oxidation pathway, where excess fatty acids may be broken down and fed back into the Krebs cycle. In normoxic conditions, however, the accumulation of pyruvate and subsequent conversion to acetyl CoA will feed into the first committed steps of ChREBP-inducible fatty acid synthesis. This hypothesis is supported by the evidence of an anticorrelation between ChREBP mRNA and PDK2 ([Table 1](#tbl1){ref-type="table"}) that may be indicative of PDK2 suppression brought about by aerobic conditions within the breast tumour microenvironment that will in turn favour the conversion of pyruvate into acetyl CoA via its downstream effect on the activation of pyruvate kinase ([@bib11]). Also, PDK2 increases accumulation of HIF-1 that may reflect the competing influences ([@bib30]). The anticorrelation with the insulin modulator TRIB3, which is activated in hypoxic conditions and is associated with increased production of lactate and increased extracellular lactate levels, would also fit with this hypothesis ([@bib27]). Interestingly, as with ChREBP in this study, TRIB3 in its protein and mRNA forms are oppositely associated with breast cancer prognosis. Despite TRIB3 being hypoxia inducible, this effect is linked to an inhibition of protein translation and redistribution of mRNA to areas within the cell that are less densely packed with ribosomes, which also takes place under anoxic conditions ([@bib35]). Further work would be needed to determine whether a similar response explains the opposite association observed with ChREBP.

ChREBP as a mediator of alternative metabolic pathways in breast tumourigenesis
-------------------------------------------------------------------------------

In hepatic tissue, ChREBP, together with sterol regulatory element-binding protein (SREBP), regulates glycolytic and lipogenic gene expression synergistically by inputting a response to increased glucose flux ([@bib15]). Increased SREBP-mediated expression of FASN has been observed in hypoxia-exposed breast tumour cell lines alongside colocalisation of SREBP with the hypoxic regions of tumours ([@bib19]). This suggests that although SREBP and ChREBP share functional similarities, their dominance may depend upon the pattern of tumour oxygenation. Further evidence that the induction or suppression of ChREBP target genes may follow a different path in the breast tumour microenvironment from that of hepatic tissue is shown by the positive correlation between ChREBP mRNA and the gluconeogenic enzyme PEPCK that was suppressed in the presence of active ChREBP in the hepatocellular carcinoma cell line investigated by [@bib22]). If, as the data of this study suggest, ChREBP is linked with normoxia, increased PEPCK expression in these conditions might correspond with the increased glucose demand of highly glycolytic but normoxic tumour tissue. This demand would potentially require supplementation via increased gluconeogenesis rather than via hypoxia-induced Glut-1 glucose transport. In contrast, in normal liver regeneration, PEPCK expression is itself increased via a hypoxia-driven HIF-1-dependent pathway ([@bib31]) unavailable in normoxic conditions.

In conclusion, our work suggests that the uptake of glucose to support a highly glycolytic phenotype in hypoxic conditions might be the primary role of glut-1 in tumours, but a secondary role is to support the diversion of glycolytic end products into fatty acid synthesis in aerobic conditions. The resulting changes in tumour metabolism may then favour activation of downstream tumourigenic pathways via activation of ChREBP-induced target genes.
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![**Immunohistochemical staining carried out according to the area and intensity of staining (0, absent; 1, light; 2, moderate; 3, heavy staining.** (**A**) The ChREBP staining (Fast Red, pink) in malignant breast compared with an absence of staining in normal adjacent tissue (**B**) in a test issue microarray (Accumax A712). In cases where normal tissue stained positively for ChREBP, this was at a lower level in both area and intensity. At places where this took place, Glut-1 (DAB, brown) in serial sections was similarly localised (**C** and **D**), whether in duct or stromal tissue (shown by arrows). Scale bar=100 *μ*m. The full colour version of this figure is available at *British Journal of Cancer* online.](bjc2013765f1){#fig1}

![**The ChREBP protein staining (Fast Red) in a human breast cancer progression array (Cybrdi CC08-00-005), showing a clear trend for increased staining score with malignant progression from normal breast to metastatic breast cancer.** (**A**) Normal breast (score 0); (**B**) mild atypical ductal hyperplasia (score 1); (**C**) intraductal carcinoma (score 2); and (**D**) metastatic nonspecific infiltrating ductal carcinoma (score 3). Scale bar=100 *μ*m.](bjc2013765f2){#fig2}

![**(A) There was a statistically significant (one-way ANOVA) trend whereby mean (median shown in brackets) ChREBP IHC score increased with malignant progression, consistent for both the Cybrdi and Accumax breast cancer progression arrays.** In contrast, however, ChREBP mRNA expression data (log2 median-centred intensity) mined from the Curtis breast series showed a clear and significant decrease with malignant progression. Further analysis (**B**) of Curtis breast series showed high (⩾median 0.1265 log2 median-centred intensity) *vs* low ChREBP (MLXIPL ILMN_1722073) mRNA expression to be a significant predictor of 5-year disease-specific survival (log rank *P-*value also shown).](bjc2013765f3){#fig3}

![**Scatter plots illustrating negative Spearman\'s rank correlations between ChREBP mRNA expression and (**A**) mean 'upregulated\' hypoxia score (*r*=−0.343, *P*=8.279e−08, *n*=232); (**B**) median 'upregulated\' hypoxia score (*r*=−0.31, *P*=8.449e−07, *n*=232); and positive correlations with (**C** and **D**) mean (*r*=0.318, *P*=7.268e−07, *n*=232) and median (*r*=0.378, *P*=2.594e−09, *n*=232) 'downregulated\' hypoxia scores (obtained from the Illumina Array data set from extended Oxf-IJB series).**](bjc2013765f4){#fig4}

![**Box plot illustrating the distribution (median, upper, lower, 25th, 75th percentiles and outliers) of mRNA expression (log2 median-centred intensity) of genes identified previously as ChREBP targets upregulated (**A**) and downregulated (**B**) in the study of [@bib22]), mined from the breast cancer Oxf-IJB (Illumina) data set (*n*=232).** Correlations with *PKLR* (puruvate kinase) were drawn from data mined using both the (GI_32967596-A) and (GI_32967596-A) identifiers (see [Table 1](#tbl1){ref-type="table"} for correlations and *P-*values).](bjc2013765f5){#fig5}

###### Spearman\'s rank correlations between carbohydrate response element-binding protein (ChREBP) and target genes previously identified by [@bib22], drawn from mRNA data mined from the breast cancer (*n*=232) Oxf-IJB \[Illumina\] data set

  **Gene symbol**         **Description**                                                             **Gene ID**    ***  R*** (***P-*****value) Oxf-IJB \[Illumina\] data set**
  ----------------------- --------------------------------------------------------------------------- -------------- -------------------------------------------------------------
  *PKLR*                  Pyruvate kinase, liver and RBC                                              NM_181871      \[GI_32967596-A\] 0.0453 (0.492)
                                                                                                                     \[GI_32967596-I\] 0.0247 (0.709)
  *SREBP1c* or *SREBF1*   Sterol-regulatory element-binding transcription factor 1                    NM_001005291   0.00517 (0.938)
  *DGAT2*                 Diacylglycerol O-acyltransferase homolog 2 (mouse)                          NM_032564      0.487 (3.141e−15)
  *PDK2*                  Pyruvate dehydrogenase kinase, isozyme 2                                    NM_002611      −0.137 (0.0370)
  *SCD1*                  Stearoyl-CoA desaturase (*δ*-9-desaturase)                                  NM_005063      0.208 (0.00147)
  *GPDI* or *GPD1*        Glycerol-3-phosphate dehydrogenase 1 (soluble)                              NM_005276      0.595 (2.2e−16)
  *TXNIP*                 Thioredoxin interacting protein                                             NM_006472      0.465 (7.58e−14)
  *INHBE*                 Inhibin, *β*E                                                               NM_031479      −0.154 (0.0189)
  *SLC6A9*                Solute carrier family 6 (neurotransmitter transporter, glycine), member 9   NM_006934      −0.0866 (0.189)
  *PEPCK* or *PCK1*       Phosphoenolpyruvate carboxykinase 1 (soluble)                               NM_002591      0.565 (\<2.2e−16)
  *G6Pase* or *G6PC*      Glucose-6-phosphatase, catalytic subunit                                    NM_000151      0.0237 (0.720)
  *TRIB3* or *C20orf97*   Tribbles homolog 3 (Drosophila)                                             NM_021158      −0.224 (0.000573)
